Usefulness of ω-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: A double-blind, randomized, placebo-controlled study

World Journal of Gastroenterology

Volumn 11, Issue 45, 2005, Pages 7118-7121

  Romano, Claudio ^a   Cucchiara, S ^b   Barabino, A ^c   Annese, V ^d   Sferlazzas, C ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d IRCCS Sanatrix   (Italy)

Author keywords

Crohn's disease; Remission maintenance; Treatment; 3 fatty acids

Indexed keywords

ARACHIDONIC ACID; CORTICOSTEROID; DOCOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; MESALAZINE; OLIVE OIL; OMEGA 3 FATTY ACID;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; ENTERIC COATED TABLET; ERYTHROCYTE MEMBRANE; FATTY ACID METABOLISM; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REMISSION; SIDE EFFECT;

EID: 31444457158     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i45.7118     Document Type: Article

References (30)

1. Rampton DS. Management of Crohn's disease. BMJ 1999; 319: 1480-1485
2. Beattie R. Therapy of Crohn's disease in childhood. Paediatr Drugs 2000; 2: 193-203
3. Kremer JM, Jubiz W, Michalek A, Rynes RI, Bartholomew LE, Bigaouette J, Timchalk M, Beeler D, Lininger L. Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Ann Intern Med 1987; 106: 497-503
4. Lawson LD, Hughes BG. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem Biophys Res Commun 1988; 152: 328-335
5. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996; 334: 1557-1560
6. Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, Scheurlen C, Koop I, Pudel V, Carr L. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol 1996; 31: 778-785
7. Kornbluth A, Salomon P, Sachard DB. Crohn's Disease. In: Sleisenger MH, Fordtrand JS, eds. Gastrointestinal Disease, 5th ed. Philadelphia: WB Saunders, 1993: 1270-1304
8. Seegers D, Bouma G, Pena AS. Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2002; 16 Suppl 4: 53-58
9. Farrell RJ, Barnerejee S, Peppercorn MA et al. Recent advances in inflammatory bowel disease. Crit Rev Clin Lab Sci 2001; 38: 33-108
10. Van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-135
11. Pestell K. New targets for Crohn's disease. Trends Pharmacol Sci 2001; 22: 342
12. Markowitz J, Grancher K, Kohn N, Daum F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am J Gastroenterol 2002; 97: 928-932
13. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104-111
14. Barabino A, Torrente F, Ventura A, Cucchiara S, Castro M, Barbera C. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther 2002; 16: 1125-1130
15. Fefferman DS, Alsahli M, Lodhavia PJ, Shah SA, Farrell RJ. Re: Triantafillidis. -Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. Am J Gastroenterol 2001; 96: 2510-2511
16. Lee T.H. Hoover RL, Williams D. Effect of dietary enrichment with EPA and DHA acids on in vitro neutrophils and monocytes leukotrienes generation and neutrophil function. N Engl J Med 1985; 312: 1217-1224
17. Kim YI. Can fish oil mantain Crohn's Disease in remission ? Nutr Rev 1996; 54: 248-252
18. Von Schacky C, Fisher S, Weber PC. Long-term effects of dietary marine n-3 fatty acids upon plasma and cellular lipids, platelet function and eicosanoid formation in humans. J Clin Invest 1985; 76: 1626-1631
19. Weber PC. Iatrogenic complications from chronic ear surgery. Otolaryngol Clin North Am 2005; 38: 711-722
20. Mc Call TB, O' Learly D, Bloomfield J et al: Therapeutic potential fish oil in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1989; 3: 415-424
21. Salomon P, Kornbluth AA, Janowitz HD. Treatment of ulcerative colitis with fish oil n-3-omega-fatty acid: an open trial. J Clin Gastroenterol 1990; 12: 157-161
22. Hawthorne AB, Daneshemend TK, Hawkey CJ. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992; 33: 922-928
23. Strasser T, Fisher S, Weber PC. Leukotriene B5 is formed in human neutrophils after dietary supplementation with eicosapentanoic acid. Proc Natl Acad Sci USA 1985; 82: 1540-1543
24. Lorenz R, Weber PC, Szimnau P, Heldwein W, Strasser T, Loeschke K. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease-a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med Suppl 1989; 731: 225-2322
25. Geerling BJ, Badart-Smook A, van Deursen C, van Houwelingen AC, Russel MG, Stockbrugger RW, Brummer RJ. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000; 6: 77-84
26. Eliakim R, Rachmilewitz D. Gastric lymphoma-an infectious disease? Harefuah 1994; 127: 541-543
27. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994; 344: 859-861
28. Wood AJJ. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-848
29. Goncalves E, Almeida LM, Dinis TC. Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: a synergistic interaction? Free Radic Res 1998; 29: 53-66
30. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004; 10: PI126-PI131